Search

Home > New FDA Approvals > 055 - Hydroxyurea for sickle cell anemia; Brimonidine tartrate ophthalmic solution for ocular redness; Procysbi for expanded indication; FDA approves first shock wave device to treat diabetic foot ulcers; FDA approves Mylan's vaginal cream; NDA for Azedra
Podcast: New FDA Approvals
Episode:

055 - Hydroxyurea for sickle cell anemia; Brimonidine tartrate ophthalmic solution for ocular redness; Procysbi for expanded indication; FDA approves first shock wave device to treat diabetic foot ulcers; FDA approves Mylan's vaginal cream; NDA for Azedra
Category: Science & Medicine
Duration: 00:12:03
Publish Date: 2018-01-02 07:00:00
Description:

January 2, 2018

0:58 - FDA approves sickle cell anemia drug (12/21) https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm590096.htm

2:27 - FDA approves Valeant's brimonidine tartrate ophthalmic solution for ocular redness (12/22) http://ir.valeant.com/news-releases/2017/12-22-2017-200318686 4:14 - Horizon Pharma (HZNP) Procysbi approved by FDA for expanded indication (12/27) http://ir.horizon-pharma.com/news-releases/news-release-details/horizon-pharma-plc-announces-fda-approval-expand-indication?_ga=2.200876590.1647061956.1514891328-2050654732.1514891328

5:42 - FDA approves first shock wave device to treat diabetic foot ulcers (12/28) FDA permits marketing of device to treat diabetic foot ulcers 7:42 - FDA approves Mylan's copy of Allergan's vaginal cream (12//29)

http://newsroom.mylan.com/2017-12-29-Mylan-Adds-to-U-S-Womens-Healthcare-Portfolio-With-FDA-Approval-of-First-Generic-for-Estrace-R-Cream

8:15 - Progenics Pharmaceuticals announces FDA acceptance of new drug application for Azedra® (iobenguane I 131) in pheochromocytoma and paraganglioma (12/29)

http://ir.progenics.com/news-releases/news-release-details/progenics-pharmaceuticals-announces-fda-acceptance-new-drug

Brought to you by Nascent Medical, LLC, has a team of over 100 PhD-/MD-level writers who can write about any medical, scientific or technical topic. Contact info@nascentmc.com

 

 
Total Play: 0